De definitieve gids voor genbewerking.
★
Menu
Home Leren Nieuws
Verkennen Technologieën Ziekten Behandelingen Klinische onderzoeken Bedrijven Wetenschappers Genen Onderzoek Instellingen
Verder dan geneeskunde Landbouw Ethiek Investeren Wereldkaart
Leren & Tools Begin hier Woordenlijst A–Z Vergelijk technologieën Tijdlijn Lijsten & Rankings AI-agents ★ Opgeslagen API
Over Over ons Methodologie Databronnen Redactioneel beleid Contact Disclaimers

Begeleide weergave
Nieuw in de genetica? We leggen elk begrip uit terwijl je bladert, in gewone taal. Dezelfde pagina's, met de hulp ingebouwd.

Expertvisie
Je kent de biologie al. Alleen de inhoud, helder en compact, zonder extra uitleg. Dit is de standaardweergave.

Interfacetaal
Lichte modus

Treatment · Cancer

CTX112

An allogeneic CD19 CAR-T candidate with multiple CRISPR edits intended to make one donor's cells usable in many patients.

Phase I/II cell therapyallogeneicCAR-T
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

Eenvoudige uitleg

Ordinary CAR-T therapy is made individually from each patient's own cells, which takes weeks and costs a great deal. CTX112 starts from a healthy donor instead and uses several simultaneous CRISPR edits to stop the donor cells attacking the patient and to slow the patient's immune system destroying them, so that one batch can serve many people, off the shelf.

Dieper ingaan

CTX112 is an allogeneic anti-CD19 CAR-T candidate from CRISPR Therapeutics incorporating multiple edits to remove the endogenous T-cell receptor and MHC class I, plus potency edits intended to improve persistence. It is in trials in B-cell malignancies and has been explored in autoimmune indications; it holds FDA Regenerative Medicine Advanced Therapy designation.

Sources

Written by CRISPR Decoded editorial team Last updated Oct 27, 2026

Connected in CRISPR Decoded

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas9

Diseases

CancerLeukemia and Lymphoma

Clinical Trials

A Study of CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Genes

B2MTRAC

Companies

CRISPR Therapeutics
Alleen educatieve informatie Deze pagina is een naslagbron, geen medisch advies. Onderzoeks- en regelgevingsstatus veranderen; controleer de datum van de laatste update hierboven en verifieer belangrijke informatie bij de vermelde primaire bronnen.